A novel monoclonal antibody for detection of galectin-9 in tissue sections: Application to human tissues infected by oncogenic viruses

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Barjon, Clément ^a,b   Niki, Toshiro ^c   Vérillaud, Benjamin ^a   Opolon, Paule ^a   Bedossa, Pierre ^d   Hirashima, Mitsuomi ^c   Blanchin, Stéphanie ^e   Wassef, Michel ^f   Rosen, Hugo R ^g   Jimenez, Anne Sophie ^a   Wei, Ming ^b   Busson, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^c KAGAWA UNIVERSITY   (Japan)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^e PX Therapeutics   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1G3; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LEUKOCYTE; LIVER BIOPSY; LIVER CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR VIRUS; WESTERN BLOTTING;

EID: 84866250809     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-16     Document Type: Article

References (22)

1. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK, Nat Immunol 2005 6 1245 1252 10.1038/ni1271 16286920 (Pubitemid 43045636)
2. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, Yamauchi A, Hirashima M, Clin Immunol 2012 143 51 58 10.1016/j.clim.2012.01. 004 22341088
3. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, et al. Clin Immunol 2008 127 78 88 10.1016/j.clim.2008.01.006 18282810
4. Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. Reddy PB, Sehrawat S, Suryawanshi A, Rajasagi NK, Mulik S, Hirashima M, Rouse BT, J Immunol 2011 187 5745 5755 10.4049/jimmunol.1102105 22021615
5. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. Sehrawat S, Suryawanshi A, Hirashima M, Rouse BT, J Immunol 2009 182 3191 3201 10.4049/jimmunol.0803673 19234217
6. T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Sharma S, Sundararajan A, Suryawanshi A, Kumar N, Veiga-Parga T, Kuchroo VK, Thomas PG, Sangster MY, Rouse BT, Proc Natl Acad Sci U S A 2011 108 19001 19006 10.1073/pnas.1107087108 22052881
7. Dysregulated T cell expression of TIM3 in multiple sclerosis. Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, Hafler DA, J Exp Med 2006 203 1413 1418 10.1084/jem.20060210 16754722 (Pubitemid 43877603)
8. Lack of TIM-3 immunoregulation in multiple sclerosis. Yang L, Anderson DE, Kuchroo J, Hafler DA, J Immunol 2008 180 4409 4414 18354161
9. Underexpression of TIM-3 and Blunted Galectin-9-Induced Apoptosis of CD4+ T Cells in Rheumatoid Arthritis. Lee J, Park EJ, Noh JW, Hwang JW, Bae EK, Ahn JK, Koh EM, Cha HS, Inflammation 2011 35 2 633 637
10. The impaired immune regulation of autoimmune hepatitis is linked to a defective Galectin-9/Tim-3 pathway. Liberal R, Grant CR, Holder B, Ma Y, Mieli-Vergani G, Vergani D, Serena Longhi M, Hepatology 2012 [Epub ahead of print] 10.1002/hep.25682
11. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, et al. Blood 2009 113 1957 1966 10.1182/blood-2008-02-142596 19005181
12. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, et al. PLoS One 2010 5 9504 10.1371/journal.pone.0009504 20209097
13. Increased expression of distinct galectins in multiple sclerosis lesions. Stancic M, van Horssen J, Thijssen VL, Gabius HJ, van der Valk P, Hoekstra D, Baron W, Neuropathol Appl Neurobiol 2011 37 654 671 10.1111/j.1365-2990.2011. 01184.x 21501208
14. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M, Nobumoto A, Niki T, Saita N, Ito K, et al. Arthritis Rheum 2007 56 3968 3976 10.1002/art.23076 18050192 (Pubitemid 350262324)
15. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, Nishi N, Hirashima M, J Biol Chem 2009 284 32344 32352 10.1074/jbc.M109.035196 19776007
16. Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1. Nishi N, Abe A, Iwaki J, Yoshida H, Itoh A, Shoji H, Kamitori S, Hirabayashi J, Nakamura T, Glycobiology 2008 18 1065 1073 10.1093/glycob/cwn089 18796645 (Pubitemid 352762841)
17. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T, FEBS Lett 2005 579 2058 2064 10.1016/j.febslet.2005.02.054 15811318 (Pubitemid 40469670)
18. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al. Blood 2012 119 13 3064 3072 10.1182/blood-2011-06-360321 22323453
19. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL, Blood 2012 119 16 3734 3743 10.1182/blood-2011-11-392951 22383801
20. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. Pioche-Durieu C, Keryer C, Souquere S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, Middeldorp J, Busson P, J Virol 2005 79 13326 13337 10.1128/JVI.79.21.13326- 13337.2005 16227255 (Pubitemid 41508147)
21. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, et al. J Immunother 2010 33 983 990 10.1097/CJI.0b013e3181f3cbf4 20948438
22. Effective treatment of metastatic forms of epstein-barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, et al. Cancer Res 2012 72 1116 1125 10.1158/0008-5472.CAN-11-3399 22282657